Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.
Pediatric cancer patients in low- and middle-income countries had a nearly 16-fold higher risk of all-cause mortality within 30 days of presentation, when compared with their counterparts in high-income countries.
In the year before the RACE Act was implemented, none of the approved therapies required pediatric study, but 92% of them had a mechanism of action that would necessitate pediatric studies under the RACE Act.